P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Clinical Pharmacology

Background:

• Clopidogrel is a crucial antiplatelet medication used after coronary interventions.
• Poor response to clopidogrel is linked to adverse cardiovascular outcomes.
• Variability in clopidogrel response may be influenced by genetic factors, specifically single nucleotide polymorphisms (SNPs) in the P2RY12 gene.

Purpose of the Study:

• To investigate the association between specific P2RY12 gene SNPs and platelet response to clopidogrel.
• To determine if these genetic variations predict clopidogrel non-response in patients with coronary heart disease.

Main Methods:

• Fifty patients with stable coronary heart disease undergoing percutaneous coronary intervention were enrolled.
• Platelet aggregation response to clopidogrel was measured using light-transmitted aggregometry before and after treatment initiation.
• Analysis included genotyping for P2RY12 SNPs: c.-15+742C > T, c.-180+2739T > C, and c.18C > T.

Main Results:

• A higher proportion of clopidogrel non-responders were observed in individuals with the 18C > T[T/T] genotype (p = 0.05).
• The 742C > T[T/T] genotype was associated with significantly higher platelet aggregation compared to other variants (p = 0.03).
• The 18C > T[T/T] genotype was identified as an independent predictor of poor response to antiplatelet therapy (p < 0.05).

Conclusions:

• The c.18C > T single nucleotide polymorphism in the P2RY12 gene may be an independent predictor of clopidogrel's pharmacological response.
• Genetic variations in P2RY12 could explain some of the variability in cardiovascular risk associated with clopidogrel therapy.
• Further large-scale prospective studies are warranted to confirm these findings and evaluate clinical implications.